hypertension, type 2 DM, dyslipidemia) A meta-analysis of 22 trials involving over 17,000 patients determined that 50.2% and 17.5% of patients treated with GLP-1RAs (exenatide, semaglutide & liraglutide) experienced a weight loss of 5% and 10% compared to placebo, and that patients without type 2 diabetes achieved a significantly greater weight loss compared to those with diabetes (Vosoughi et al, 2022)
Second: your body will tell you loud and clear (fullness, nausea, reflux)
But, over time, newer, more advanced GLP-1s have come to market, with even longer release times (no offense, Gila monsters)
I generally do not prescribe GLP-1 RAs myself unless local systems and my own scope make it straightforward to manage metabolic monitoring, but I document why I think the patient would benefit and communicate directly with the prescribing clinician
PDUFA Date and Launch If the NDA is filed Q4 2026, expect FDA action around late 2027 (priority review) or Q1 2028 (standard review), with commercial launch following 13 months later for manufacturing and distribution setup
How to Use Ozempic
